The stock of Altamira Therapeutics Ltd. (NASDAQ:CYTO) last traded at $5.22, down -0.19% from the previous session.
Data from the available sources indicates that Altamira Therapeutics Ltd. (NASDAQ:CYTO) is covered by 1 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $286.10 and a low of $286.10, we find $286.10. Given the previous closing price of $5.23, this indicates a potential upside of 5370.36 percent. CYTO stock price is now -20.81% away from the 50-day moving average and -61.18% away from the 200-day moving average. The market capitalization of the company currently stands at $6.06M.
In total, 0 analysts have assigned it a hold rating, and 1 have given it a buy rating. Brokers who have rated the stock have averaged $286.10 as their price target over the next twelve months.
A total of 10.04% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CYTO stock. A new stake in Altamira Therapeutics Ltd. shares was purchased by VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC during the first quarter worth $3,000. SIMPLEX TRADING, LLC invested $2,000 in shares of CYTO during the first quarter. In total, there are 15 active investors with 1.30% ownership of the company’s stock.
With an opening price of $5.44 on Thursday morning, Altamira Therapeutics Ltd. (NASDAQ: CYTO) set off the trading day. During the past 12 months, Altamira Therapeutics Ltd. has had a low of $4.60 and a high of $66.60. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 0.80, and a quick ratio of 0.60. The fifty day moving average price for CYTO is $6.59 and a two-hundred day moving average price translates $13.45 for the stock.
The latest earnings results from Altamira Therapeutics Ltd. (NASDAQ: CYTO) was released for Dec, 2021. For the current quarter, analysts expect CYTO to generate $59.1M in revenue.
Altamira Therapeutics Ltd.(CYTO) Company Profile
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.